These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 10186462)

  • 41. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
    Hay JW; Sterling KL
    Pharmacoeconomics; 2005; 23(2):133-41. PubMed ID: 15748088
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial].
    Szucs TD; Berger K; März W; Schäfer JR
    Herz; 2000 Aug; 25(5):487-94. PubMed ID: 10992997
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.
    Lewis SJ; Sacks FM; Mitchell JS; East C; Glasser S; Kell S; Letterer R; Limacher M; Moye LA; Rouleau JL; Pfeffer MA; Braunwald E
    J Am Coll Cardiol; 1998 Jul; 32(1):140-6. PubMed ID: 9669262
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pharmacoeconomic analysis of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy for the secondary prevention of coronary heart disease].
    Sato S; Matsushita Y; Kobayashi T; Awata N
    Nihon Eiseigaku Zasshi; 2004 Jul; 59(3):335-41. PubMed ID: 15359898
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarct or unstable angina pectoris. An analysis based on the LIPID Study].
    Szucs TD; Bertel O; Darioli R; Gutzwiller F; Mordasini R
    Praxis (Bern 1994); 2000 Apr; 89(18):745-52. PubMed ID: 10823012
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
    Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
    Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project.
    Sacks FM; Tonkin AM; Shepherd J; Braunwald E; Cobbe S; Hawkins CM; Keech A; Packard C; Simes J; Byington R; Furberg CD
    Circulation; 2000 Oct; 102(16):1893-900. PubMed ID: 11034935
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A coronary primary intervention study of Japanese men: study design, implementation and baseline data. The Kyushu Lipid Intervention Study Group.
    J Atheroscler Thromb; 1996; 3(2):95-104. PubMed ID: 9226461
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease.
    Ledmyr H; McMahon AD; Ehrenborg E; Nielsen LB; Neville M; Lithell H; MacFarlane PW; Packard CJ; Karpe F;
    Circulation; 2004 May; 109(19):2279-84. PubMed ID: 15136504
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.
    Lowe G; Rumley A; Norrie J; Ford I; Shepherd J; Cobbe S; Macfarlane P; Packard C
    Thromb Haemost; 2000 Oct; 84(4):553-8. PubMed ID: 11057849
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors.
    Sacks FM; Tonkin AM; Craven T; Pfeffer MA; Shepherd J; Keech A; Furberg CD; Braunwald E
    Circulation; 2002 Mar; 105(12):1424-8. PubMed ID: 11914249
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
    Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
    Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS).
    Basso F; Lowe GD; Rumley A; McMahon AD; Humphries SE
    Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):599-604. PubMed ID: 11950697
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study.
    Caro JJ; Huybrechts KF; De Backer G; De Bacquer D; Closon MC
    Acta Cardiol; 2000 Aug; 55(4):239-46. PubMed ID: 11041122
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease--related events.
    Ito MK; Delucca GM; Aldridge MA
    J Cardiovasc Pharmacol Ther; 2001 Apr; 6(2):129-35. PubMed ID: 11509919
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study.
    Shepherd J; Gaw A;
    Med Princ Pract; 2002; 11 Suppl 2():17-30. PubMed ID: 12444307
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective?
    Perreault S; Hamilton VH; Lavoie F; Grover S
    Arch Intern Med; 1998 Feb; 158(4):375-81. PubMed ID: 9487235
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factor modification: rationale for management of dyslipidemia.
    Gotto AM
    Am J Med; 1998 Feb; 104(2A):6S-8S. PubMed ID: 9550500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.